Abstract
Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Current Pharmaceutical Design
Title:Brain Targeting of siRNA via Intranasal Pathway
Volume: 21 Issue: 31
Author(s): Chandana Mohanty, Paromita Kundu and Sanjeeb K. Sahoo
Affiliation:
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Abstract: Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Export Options
About this article
Cite this article as:
Mohanty Chandana, Kundu Paromita and Sahoo K. Sanjeeb, Brain Targeting of siRNA via Intranasal Pathway, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191737
DOI https://dx.doi.org/10.2174/138161282131151013191737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry Proteomics, and Metabolomics: Magnetic Resonance Spectroscopy for the Presurgical Screening of Thyroid Nodules
Current Genomics Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Current Pharmaceutical Design Network Theory to Understand Microarray Studies of Complex Diseases
Current Molecular Medicine The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Systemic Inflammatory Response as a Risk and Prognosis Factor in Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Immunoglobulin G Expression and its Potential Role in Primary and Metastatic Breast Cancers
Current Molecular Medicine Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch
Anti-Cancer Agents in Medicinal Chemistry Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Long non-coding RNAs in Alzheimer’s disease
Current Topics in Medicinal Chemistry Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Antiretroviral Therapy Regimens for Neuro-AIDS
Current Drug Targets - Infectious Disorders Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry